HOME >> MEDICINE >> NEWS
Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial

Copenhagen, Denmark: Eagerly awaited results from the world's first head to head trial between the anti-cancer drugs docetaxel (Taxotere) and paclitaxel (Taxol)[1] have shown that there was a better overall response rate and longer overall survival among breast cancer patients given docetaxel although docetaxel was associated with more severe side effects.

The new results were presented for the first time today (Wednesday 24 September) at ECCO 12 The European Cancer Conference taking place in Copenhagen.

Four hundred and forty nine women with advanced incurable breast cancer who had received previous treatment with an anthracycline-based chemotherapy were randomised into the Phase III trial from multiple centres across the USA between 1994 and 20012. Half were treated with paclitaxel and half were treated with docetaxel.

The trial's principal investigator, Professor Peter Ravdin, associate professor in the Department of Medicine at the University of Texas Health Science Center in San Antonio, told a news briefing that the women treated with docetaxel survived for a median 15.4 months compared with a median 12.7 months for the women who received paclitaxel.

There was an overall response rate of nearly a third among the docetaxel patients compared with a quarter for the paclitaxel patients. The median time before the breast cancer progressed (TTP) was 5.7 months for the docetaxel patients and 3.6 months for the paclitaxel patients. The results for overall survival and for TTP were statistically significantly superior for docetaxel and the overall response rate in favour of docetaxel approached statistical significance.

However, the women who received docetaxel did experience more severe side effects (grade 3/4 toxicities) with higher incidences of neutropenia (reduction in infection-fighting white blood cells), asthenia (loss of strength), infection, oedema (abnormal accumulation of fluid), mouth ulcers and neuromotor and n
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
45-3252-4163
Federation of European Cancer Societies
24-Sep-2003


Page: 1 2

Related medicine news :

1. Good intentions versus bad habits: Why the old ways win out
2. Normal aging versus Alzheimers disease and the potential for prevention
3. Regulatory T cells keep graft-versus-host disease in check
4. Study evaluates Abacavir, Lamivudine and Efavirenz versus Zidovudine, Lamivudine and Efavirenz
5. U-M study finds new target in war against graft-versus-host disease
6. Weekly Taxol (paclitaxel) plus Paraplatin (carboplatin) is safe and effective in patients with advanced lung cancer
7. International breast cancer prevention study launches in the United States and Canada
8. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
9. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/16/2018)... ... November 16, 2018 , ... ... framework agreements with China Resources Microelectronics Limited (CR Micro) and China Resources ... the possibility of establishing two joint research centres for novel micro-electronic devices ...
(Date:11/15/2018)... ... November 15, 2018 , ... ... Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) have elected Edward D. Buckingham, ... in the specialty field of facial plastics and reconstruction, while AAFPRS is an ...
(Date:11/15/2018)... ... 15, 2018 , ... Over the last decade, SABRE , the global ... for National Breast Cancer Foundation (NBCF) . A mission-driven organization and proud partner ... proceeds have helped launch the National Mammography Program which has provided almost ...
(Date:11/15/2018)... ... November 15, 2018 , ... ApriaDirect, ... now accepts Flexible Spending Account (FSA) and Health Savings Account (HSA) debit cards ... burden of healthcare spending for customers and improve the overall shopping experience. ...
(Date:11/15/2018)... ... November 15, 2018 , ... The National Cancer Institute estimates that 1.7 million ... primary risk factor for cancer and we typically associate the disease with old age, ... And with aggressive treatment and advanced therapies, increasing numbers of these patients survive their ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... ... November 16, 2018 , ... Drake’s Organic Spirits ... Certification by the globally-recognized and respected Vegan Awareness Foundation. Drake’s is the ... Vegan, Non-GMO Project Verified, Gluten-Free and Kosher. , Many consumers assume ...
(Date:11/15/2018)... (PRWEB) , ... November 15, 2018 , ... Ric Henry, ... Health Care Center in Truth or Consequences, New Mexico on Friday, November 2, 2018. ... President of the Center’s Board of Directors. , Sierra Health Care Center has ...
(Date:11/15/2018)... ... November 15, 2018 , ... Catalent Pharma ... drugs, biologics and consumer health products, today announced that Pete Young, Director of ... Partnerships in Clinical Trials (PCT) conference at the CCIB Convention Centre Barcelona, Barcelona, ...
Breaking Medicine Technology:
Cached News: